AMINOSYN 8.5% W/ELECTROLYTES Drug Patent Profile

When do Aminosyn 8.5% W/electrolytes patents expire, and when can generic versions of Aminosyn 8.5% W/electrolytes launch?

Aminosyn 8.5% W/electrolytes is a drug marketed by Icu Medical Inc and is included in one NDA.

The generic ingredient in AMINOSYN 8.5% W/ELECTROLYTES is amino acids; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic. There are three hundred and fifty drug master file entries for this compound. Additional details are available on the amino acids; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic profile page.

Summary for AMINOSYN 8.5% W/ELECTROLYTES

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AMINOSYN 8.5% W/ELECTROLYTES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Icu Medical Inc	AMINOSYN 8.5% W/ELECTROLYTES	amino acids; magnesium chloride; potassium chloride; sodium chloride; sodium phosphate, dibasic	INJECTABLE;INJECTION	017673-009	Oct 25, 2002		DISCN	No	No

Investment Scenario and Fundamentals Analysis for AMINOSYN 8.5% W/ELECTROLYTES

Last updated: February 4, 2026

Overview

AMINOSYN 8.5% W/ELECTROLYTES is an amino acid formulation used for parenteral nutrition in hospital settings. Its market is driven by clinical demand for amino acid solutions and the broader hospital nutrition market, which is generally characterized by steady growth, especially in aging populations and regions with expanding healthcare infrastructure.

Market Environment

• Market Size and Growth: The global intravenous (IV) amino acids market was valued at approximately USD 600 million in 2022. It is projected to expand at a compound annual growth rate (CAGR) of 6-8% until 2027[1].

• Key Drivers: Aging populations in North America, Europe, and parts of Asia increase prevalence of malnutrition and chronic diseases requiring parenteral nutrition (PN). The rise of outpatient PN and ICU admissions sustains demand.

• Competitive Landscape: Major players include Baxter, Fresenius Kabi, and B. Braun. New entrants must navigate established supply chains and regulatory approvals.

• Regulatory Status: AMINOSYN 8.5% W/ELECTROLYTES is generally approved by FDA and EMA for hospital use, with regional variations. The drug’s approval status influences market access and sales potential.

Product Fundamentals

• Formulation: The solution contains amino acids aminoacetate, electrolytes (such as sodium, potassium, and chloride), and water for injection. Its 8.5% concentration positions it as a higher-concentration option for adult patients.

• Manufacturing and Supply Chain: Production relies on high-purity raw materials and sterile manufacturing environments. Supply chain stability relates to sourcing quality amino acids and electrolytes, especially amid raw material shortages.

• Pricing Strategy: Pricing varies by region; in the US, IV amino acid solutions range from USD 10-20 per liter. AMINOSYN’s competitive positioning depends on formulation uniqueness, volume, and contractual agreements with hospitals.

Financial and Investment Considerations

• Profitability: Typically, hospital drugs have high gross margins due to low variable costs but face price pressures from payers and procurement contracts.

• Market Penetration and Growth: Market share depends on product differentiation, clinical familiarity, and formulary access.

• Regulatory Risks: Delays or rejections in regulatory approvals can dampen sales prospects.

• Intellectual Property: There are generally no patents on formulations like AMINOSYN; however, manufacturing processes and delivery systems may be patented, affecting generics and biosimilars.

Risks and Opportunities

• Risks: Regulatory non-compliance, supply chain disruptions, pricing pressures, and shift toward alternative nutritional products.

• Opportunities: Expansion into emerging markets, product line extensions, and positioning within outpatient and home-care settings.

Conclusion

Investing in AMINOSYN 8.5% W/ELECTROLYTES involves understanding its stable yet competitive market backdrop, manufacturing complexities, and regulatory environment. Its prospects hinge on hospital demand for parenteral nutrition amid demographic trends and healthcare infrastructure development.

---

Key Takeaways

• The market for IV amino acid solutions is growing 6-8% annually globally, driven by aging populations and increasing medical needs.
• AMINOSYN 8.5% W/ELECTROLYTES faces competition from established players but benefits from hospital preferences for standardized formulations.
• Supply chain stability and regulatory compliance are critical for sustained sales.
• Profitability relies on maintaining low production costs and favorable reimbursement agreements.
• Expansion avenues exist in emerging markets and outpatient care but require strategic planning.

---

FAQs

1. What are the main drivers for demand for parenteral amino acid solutions like AMINOSYN?
   Increasing prevalence of malnutrition, chronic diseases, and ICU admissions, primarily in aging populations, drive demand.

2. How does regulatory approval influence market access?
   FDA and EMA approvals standardize market entry. Variations or delays in approvals in specific regions can restrict sales and expansion.

3. What pricing strategies impact profitability?
   Competitive pricing aligned with hospital procurement contracts, volume discounts, and formulary positioning influence margins.

4. What risks threaten continued success in this market?
   Regulatory setbacks, raw material shortages, and pricing pressure from payers challenge sustained profitability.

5. Are there growth prospects outside traditional hospital settings?
   Yes; outpatient and home-care markets present expansion opportunities but require adaptation of supply and clinical protocols.

---

References

[1] MarketsandMarkets, "Intravenous (IV) Amino Acid Solution Market," 2022.